Slide 1: Market Release: Corum investing for growth
Corum Group Limited ABN 25 000 091 305 Level 3, 120 Sussex Street, Sydney NSW 2000 www.corumgroup.com.au Market Release 10 February 2022 Corum investing for growth Corum Group Limited (ASX: COO) (Corum) is pleased to announce its interim results for FY22. • Group revenue $6.1m up 4% on pcp • Underly
Slide 2: About Corum Group
About Corum Group Corum Group Limited [ASX:COO] (Corum) is an Australian company limited by shares that owns businesses in technology and software development. For more than 30 years Corum has been using its deep industry expertise and extensive relationships to develop Point-Of-Sale, Dispensing and
Slide 3: Corum Group Limited H1 FY22 Results
Corum Group Limited H1 FY22 Results 10 February 2022
Slide 4: Important Notice & Disclaimer
Important Notice & Disclaimer This presentation has been prepared by Corum Group Limited (COO or the assurance that the results, performance or achievements expressed or implied by Company or Corum). It should not be considered as an offer or invitation to the forward-looking statements contained in
Slide 5: H1 FY22 Key Highlights
H1 FY22 Key Highlights Financials • Health Services revenue $6,101k, an increase of 4% on pcp • Operating cashflow $2,324k in the period compared to $2,259k in pcp, up 3% • Underlying EBITDA $1.7m(1) compared to $2.2m(2) in pcp, down 22% • Underlying NPAT of $0.4m(1) compared to $1.5m(3) in pcp, dow
Slide 6: H1 FY22 Key Highlights
H1 FY22 Key Highlights PharmX expansion and growth • YTD supplier-to-pharmacy connections growth of 10% • Retail group agreements signed with key retail pharmacy groups to drive utilisation. Agreements signed in H1 FY22 represent approximately 800 pharmacies including TerryWhite Chemmart, Blooms the
Slide 7: Delivering our strategy for PharmX
Delivering our strategy for PharmX Increase the number of suppliers • Making it easier for suppliers to connect Improving pharmacy utilisation rates • Incentivising pharmacies to increase usage • Agreements struck with large groups Developing new functionality • Current PharmX business model doesn’t
Slide 8: PharmX Growth
PharmX Growth New Retail Group Agreements are beginning to deliver an uplift in utilisation rates, and an increase in the number of supplier-to-pharmacy connections. Lead indicator – total existing 18% Current active Pharmacy to connections (excluding supplier certain customer connections volume red
Slide 9: Regaining our Market Share
Regaining our Market Share Strategy remains unchanged • Entry through Head Office expertise. 90% of pharmacies are now affiliated with a group, banner, brand or buying groups • Regaining market share by targeting these groups through our relationships and market leading Head Office product • Build o
Slide 10: H1 FY22 Summary
H1 FY22 Summary Revenue growth & generating PharmX Growth Healthtech Focus cash Revenue growth of 4%, below our Strategy in place to super charge Now having disposed of aim of 15% growth. returns from this valuable industry eCommerce, we are a fully focused asset. healthtech business looking to Heal
Slide 11: Financials
Financials
Slide 12: H1 FY22 Financial Snapshot
H1 FY22 Financial Snapshot Revenue growth continues, EBITDA remains positive Results1 H1 FY22 H1 FY21 ∆ PCP Sales Revenue ($000’s)3 Revenue $6,101 $5,862 4% H2 $7,352 H2 Underlying Expenses ($4,404) ($3,673) 20% $6,473 H2 H2 $5,348 H2 $4,813 H2 $5,996 EBITDA (reported) $1,385 $1,417 -2% $4,605 H1 H1
Slide 13: Revenue Bridge
Revenue Bridge Health revenue growth was +4% on pcp. Excluding certain customer volume reductions and some non-recurring government development funding received in H1 FY21, revenue growth was +9%. The underlying growth has been generated mainly through increased PharmX utilisation. $6,200 +9% +4% $6
Slide 14: Underlying EBITDA and NPAT Bridge
Underlying EBITDA and NPAT Bridge Revenue growth continues, investment into people drives decline in EBITDA Underlying EBITDA Bridge(1) 239 (591) (121) (19) 2,189 #039;000 1,697 H1 FY21 Underlying Revenue growth Increase in underlying Increase in technology Other H1 FY22 Underlying EBITDA people costs
Slide 15: Continued Positive Cashflow
Continued Positive Cashflow Net cash from / (Used in) Operating Activities (#039;000)1 • Operating cashflow of +$770k excluding R&D benefit, and +$2,324 including net R&D tax incentive received. $903 $770 $559 $191 • Receipts from customers have continued to grow and are up 3% HoH, and up 16% on pcp dr
Slide 16: Questions
Questions
Slide 17: Appendix
Appendix
Slide 18: Corporate Overview
Corporate Overview Corum Group Limited (ASX:COO) at 28 Jan 22 Capital Structure Share Price 6.8cps Shares on Issue (m) 596.8 Market Capitalisation $40.58m Options / Perf Rights (m) 7.0 Enterprise Value (Cash 31/12/21) $34.20m Diluted Issued Capital (m) 603.8 Share Price Performance 12c 8 Volume (m)
Slide 19: Profit & Loss
Profit & Loss Profit & Loss (A$000's) H1'21 H2'21 FY'21 H1'22 ∆ PCP Revenue $5,862 $6,013 $11,875 $6,101 4% Health $5,862 $6,013 $11,875 $6,101 4.1% Expenses Materials and consumables ($867) ($732) ($1,599) ($828) -4.5% Employee Benefits ($2,881) ($3,188) ($6,069) ($3,098) 7.5% Marketing ($58) ($103
Slide 20: Balance Sheet
Balance Sheet Balance Sheet (A$000's) 31 Dec 21 - H1 FY22 30 June 21 - FY21 Current assets Cash and cash equivalents $6,381 $6,478 Trade and other receivables $916 $848 Inventories $59 $34 Income tax receivable $675 $1,548 Other assets $363 $298 Assets related to discontinued operations $1,218 $1,21
Slide 21: Cashflow
Cashflow Cash flow (A$000's) H1 FY22 #039;000 H1 FY21 #039;000 Cash flows from operating activities Receipts from customers $6,682 $5,742 Payments to suppliers and employees ($5,990) ($5,329) Interest and other revenue received $13 $91 Income tax paid ($433) ($273) Research and development incentive $1,98
Slide 22: Share Registry
Share Registry Top holders as of 28 January 2022 Rank Name Units % Units 1 LUJETA PTY LTD <MARGARET A/C> 95,746,043 16.04% 2 ARROTEX INVESTMENTS HOLDING 1 PTY LTD 60,000,000 10.05% 3 NATIONAL NOMINEES LIMITED 38,742,512 6.49% 4 MERSAULT PTY LTD <ENGLAND S/F A/C> 26,766,667 4.49% 5 MR DAVID GERALD MA
Slide 23: Corum Group Limited
Corum Group Limited Contact: Investor.Relations@corum.com.au